Digest Network Come funziona
Network
/
Società
En
Non verificato

Enanta Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniMedicina - VarieSalute

45 comunicati stampa

Guarda tutti i comunicati
18/06/2026
Industria
Infanzia
Biotecnologia
Assistenza all'Infanzia
Salute
Sanità
Farmaceutica
HIV, AIDS e malattie autoimmuni
Vetrine/Shopping
Medicina - Varie
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
28/05/2026
Web e Social Network
Eventi
Fiere
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Medicina - Varie
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
11/05/2026
Eventi
Mercato azionario
Salute
Igiene alimentare
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/05/2026
Web e Social Network
Eventi
Fiere
Industria
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
13/04/2026
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/04/2026
Eventi
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/03/2026
Eventi
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/03/2026
Web e Social Network
Eventi
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
10/02/2026
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Sanità
Medicina - Varie
Farmaceutica
Eventi
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
09/02/2026
Eventi
Mercato azionario
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0